Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Insider Sells $6,472,500.00 in Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $25.89, for a total value of $6,472,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

YMAB traded up $0.18 during midday trading on Friday, hitting $22.82. The company’s stock had a trading volume of 48,330 shares, compared to its average volume of 73,132. The stock has a market capitalization of $780.31 million and a price-to-earnings ratio of -15.21. Y-mAbs Therapeutics, Inc has a 52-week low of $15.17 and a 52-week high of $31.00.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.11). Equities research analysts predict that Y-mAbs Therapeutics, Inc will post -1.67 EPS for the current year.

Several research firms have commented on YMAB. Zacks Investment Research cut Y-mAbs Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 20th. HC Wainwright began coverage on Y-mAbs Therapeutics in a report on Monday, April 1st. They issued a “buy” rating and a $36.00 price target for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $30.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in YMAB. Citigroup Inc. acquired a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $37,000. Strs Ohio acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $38,000. BNP Paribas Arbitrage SA acquired a new position in Y-mAbs Therapeutics during the 1st quarter worth approximately $38,000. American International Group Inc. acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $93,000. Finally, Bank of America Corp DE lifted its position in Y-mAbs Therapeutics by 3,056.5% during the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after acquiring an additional 5,838 shares in the last quarter. 25.41% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Insider Sells $6,472,500.00 in Stock” was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/04/y-mabs-therapeutics-inc-ymab-insider-thomas-gad-sells-250000-shares.html.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: How Investors Can Profit from Options Trading

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.